Prestigious Molecular Biology Journal Publishes Breakthrough Research Led by Dr. Andres Tellez: Milestone Achievement Reflects Robust Brain Trust at Biocodex USA

SAN BRUNO, Calif.--()--Biocodex USA is pleased to announce that Dr. Andres Tellez, principal, business development and strategy, served as the lead author on a research article published in The Journal of Molecular Biology, entitled “Interstitial contacts in an RNA-dependent RNA polymerase lattice.” The manuscript describes the development, refinement, and experimental validation of a computational method for identifying protein-protein interaction sites. The method holds significant implications for the rational design of new therapeutic agents because of the functionally important protein-protein interactions it can predict. These macromolecular interactions are a fundamental basis of all cellular processes, including the human immune system’s recognition of, and response to, pathogens such as viruses.

“This work builds upon my previously published article in The Journal of Molecular Biology which combines computation modeling and traditional experimental techniques to gain new insights into protein-protein interactions,” said Dr. Tellez. “The approach I used in my research has helped me identify some key biochemical characteristics and mechanisms of action that I now actively use as metrics when evaluating therapeutic candidates for Biocodex USA,” commented Dr. Tellez.

Dr. Tellez designed the computational methodology used to predict the protein-protein interaction, then cloned and purified viral proteins with mutations in them that would specifically address the hypothesized interaction. He also carried out the in vitro biochemical experiments to test and verify the computational model.

The Kirkegaard Lab at Stanford and the Bullitt Lab at Boston University initially discovered the RNA polymerase lattices and established the scientific foundations that enabled Dr. Tellez’s research. Members of both labs helped design and execute experiments to further test the computational model, using electron microscopy as well as live virus in human HeLa cells.

“Biocodex USA supports and encourages our team to remain devoted to contributing to scientific breakthroughs through active participation in outside research activities,” said Marc Rohman, U.S. executive vice president and general manager of Biocodex USA. “Dr. Tellez’s brilliant manuscript is testimony to that commitment and adds another invaluable dimension to the 50 years of combined clinical experience along with science-based expertise our growing team has to offer.”

Dr. Tellez joined Biocodex USA in January, 2011. His educational background includes a PhD in Biomedical Informatics from Stanford University, and a Master’s and Bachelor’s in Computer Science from The Massachusetts Institute of Technology (MIT). His research combined distributed computing, in vitro biochemistry and electron microscopy to investigate novel drug targets in RNA viruses. Dr. Tellez remains affiliated with Stanford University as a visiting scholar in Professor Karla Kirkegaard’s Lab.

Dr. Tellez is the third Stanford University graduate to be hired by Biocodex USA. Dr. Tellez joins Dr. Rajesh Gupta, director of medical, scientific and regulatory affairs, and Daniel Lopez, economics and analytics specialist.

Visit to view the manuscript abstract and for ordering information for the full text.

Visit to view a photo of Dr. Tellez.

About Biocodex:

Biocodex is a privately held pharmaceutical company based in Gentilly, France, and maker of Florastor® and Florastor® Kids probiotic supplements. Founded in 1953 by Michael Hublot and Francois Vallet, Biocodex specializes in three therapeutic areas—gastroenterology, neurology, and psychiatry and pain treatment. Biocodex products are present, in various forms and names, in some 100 countries.

About Florastor®:

Florastor® and Florastor® Kids, both yeast-based probiotics are Biocodex’s flagship products. Florastor® is the world’s most widely used probiotic and has been recommended by doctors around the globe for more than 50 years because it works. Florastor® contains Saccharomyces boulardii lyo, a friendly yeast. Florastor® is beneficial for people who look to promote intestinal health and keep their intestines functioning well. First available in Europe in 1953, Florastor® is now trusted in more than 100 countries around the globe. Infants as young as two months can take Florastor® Kids, which is available as a kid-friendly, tutti-frutti-flavored, powder packet.

For more information, visit or


The Reilly Group
Susan Reilly, 773-348-3800


The Reilly Group
Susan Reilly, 773-348-3800